Allele Biotechnology

Allele Biotechnology is a specialized biotech firm focused on enabling advanced cell therapies through its integrated platform of next-gen mRNA reprogramming, GMP iPSC generation, and genome editing. Operating as both a technology innovator and a contract development and manufacturing organization (CDMO), it serves pharmaceutical and biotech partners worldwide. Its core value proposition lies in accelerating the path to clinic for iPSC-based therapeutics by providing scientifically robust, clinically compliant tools and services. The company combines proprietary mRNA technology with deep cGMP experience to address critical bottlenecks in cell therapy development and manufacturing.

Integrated platform featuring next-generation mRNA reprogramming for non-integrating iPSC generation, GMP-compliant iPSC banking, precision genome editing (CRISPR), and over two dozen validated differentiation protocols.

Allele competes in the specialized iPSC-focused CDMO and enabling technology space. Competitors range from large, diversified CDMOs (e.g., Lonza, Catalent) to other stem cell-specialized service providers and biotech firms with proprietary reprogramming technologies. Allele differentiates through its integrated 'all-in-one' iPSC-focused offering and claimed leadership in cGMP iPSC innovation.